National Agri-Marketing Association
NAMA Website
Upcoming Events
Agri-Marketing Conf
Best of NAMA 2017
Member Directory

Source: Zoetis news release

Zoetis will offer two oral presentations and one poster presentation featuring data on APOQUEL® (oclacitinib tablet), the first and only Janus kinase (JAK) inhibitor approved for veterinary use during the North American Veterinary Dermatology Forum (NAVDF) in Phoenix, Ariz., April 9-12.

At the conference, the company will also award three Excellence in Dermatology™ Research Grants. The goal of this annual grant program is to support research in the area of basic science diagnosing and treating dermatologic conditions in dogs and cats.

"Zoetis is committed to research and development programs that address the real world challenges veterinarians face every day," said Catherine Knupp, DVM, MS, executive vice president and president, Research and Development, Zoetis. "Our scientists are focusing on finding innovative solutions to the unmet needs of our veterinary customers.

APOQUEL is an example of a novel treatment that safely and effectively addresses skin conditions frequently seen by veterinarians, that also helps enhance the quality of life of their clients and patients."

Data Presented at NAVDF

• 4/10, 4:15 p.m. "Efficacy and safety of oclacitinib (APOQUEL) compared to prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs"

• 4/10, 4:30 p.m. "Efficacy and safety of oclacitinib (APOQUEL) compared to cyclosporine (Atopica, Novartis Animal Health) for the control of atopic dermatitis in client-owned dogs"

The above oral presentations will take place in the Phoenix Ballroom D/E. The poster presentation, "PK/PD of oclacitinib (APOQUEL) in an IL-31 induced model of pruritus in the dog," will be on display in Phoenix Ballroom C.

As Zoetis continues to invest in research to identify innovative solutions for unmet needs, exploratory research will also be presented evaluating the role of alternative mechanisms in pruritus associated with allergic skin disease using a canine model of flea allergic dermatitis.

2014 Excellence in Dermatology Grant Recipients

Jennifer Schissler Pendergraft, DVM, MS, DACVD, and co-investigator Andrew Simpson, DVM, of Colorado State University James L. Voss Veterinary Teaching Hospital, will receive a grant for their project, "Frequency of urinary tract infection in dogs treated with oclacitinib (APOQUEL) for cutaneous hypersensitivity: a prospective study."

A second grant is awarded to Rosanna Marsella, DVM, DACVD, and co-investigators Ha Jung Kim, DVM, PhD, and Dunbar Gram, DVM, DACVD, of the University of Florida, for "Investigation of the effect of oclacitinib on Thymic Stromal Lymphopoietin expression, skin barrier function and ability to prevent allergic sensitization in atopic dogs."

Douglas DeBoer, DVM, DACVD, of the University of Wisconsin Madison, receives a grant to study "Serum Vitamin D levels in dogs with atopic dermatitis."

The grant recipients will be recognized at the NAVDF on Thursday, April 10, at 11:00 a.m.

More information about Excellence in Dermatology is available at, and information about APOQUEL can be found at

Search News & Articles

Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © 2017, Henderson Communications LLC. | User Agreement